Recommended Global Immunology Webinars & Conferences

Europe & UK

Pharma Europe 2024, Switzerland BIOSIMILARS 2024, UK Advanced Chromatography 2024, Italy PHARMACEUTICAL SCIENCES 2024, UK

Asia Pacific & Middle East

HUMAN METABOLISM 2024, UAE biofuels-bioenergy 2024, UAE HEART BRAIN 2023, UAE Business Summit 2024, UAE

Canada

Chromatography Techniques-2024, Canada Annual Mental Health 2024, Canada Applied Microbiology 2024, Canada Cosmetic Dentistry Conference 2024, Canada

Antibiotics 2024

Welcome Message

Conference Series welcomes attendees, presenters, and exhibitors from all over the globe. We are delighted to invite you all to attend and register for the “11^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance” which is scheduled during March 14-15, 2024 in London, UK.

Join us at the "Antibiotics 2024" conference, where leading researchers, clinicians, and policymakers will gather to discuss the challenges and innovations in combating antibiotic resistance. This multidisciplinary event will feature keynote lectures, interactive workshops, and panel discussions focused on understanding the mechanisms of resistance, optimizing antibiotic use, and developing novel therapeutic strategies. Attendees will have the opportunity to network with experts in the field and explore the latest breakthroughs in antibiotic research. Together, we can work towards preserving the effectiveness of antibiotics and ensuring a healthier future for all.

Antibiotics 2024 has been designed in an interdisciplinary manner with a multitude of tracks to pick from every segment and provides you with a novel opportunity to satisfy up with peers from both industry and academia and establish a scientific network between them. We cordially invite all concerned people to come to join us at our event and make it successful by your participation.

About Conference

After a successful conference of Antibiotics 2023, we are currently bringing forth “11^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2024) slated on March 14-15, 2024 in London, UK. Antibiotics 2024 welcomes attendees, participants, students, speakers, organizing committee members, delegates from all over the world. We welcome you and appreciate your participation at the London, UK and it will be organized around the theme" Use antibiotic wisely-Prevent antimicrobial resistance" which includes prompt Keynote presentations, Oraltalks, Poster presentations and Exhibitions.

Antibiotics 2024 will be organizing offering best platform to all academicians, researchers, industry professional, and scholars. It will be scheduled on wide range of topics and it will be helpful for scientific fraternity to be connected while staying at their preferred place. Join the Physical Conference organized by us and let the world know about your research and innovation. The Antibiotics 2024 conference hosting presentations from editors of eminent refereed journals, renowned and active investigators and decision makers in the field of Pharmacology, Infectious Diseases, Microbiology, Immunology, Bacteriology and many more. Antibiotics 2024 Organizing Committee also invites young investigators at each and every career stage to submit abstracts reporting their latest scientific research in oral and poster sessions.

Antibiotics 2024 is intended to honour prestigious award for talented Young researchers, Scientists, Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, junior faculty in recognition of their outstanding contribution towards the conference theme. The Young Scientist Awards make every effort in providing a strong professional development opportunity for early career academicians by meeting experts to exchange and share their experiences on all aspects of Pharmacology.

Young Research’s Awards at Antibiotics 2024 for the Nomination:

Young Researcher Forum - Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation and only 25 presentations acceptable at the Antibiotics 2024

YRF Registration benefits:

Our conferences provide best Platform for your research through oral presentations.
Share the ideas with both eminent researchers and mentors.
Young Scientist Award reorganization certificate and memento to the winners
Young Scientists will get appropriate and timely information by this Forum.
Platform for collaboration among young researchers for better development
Award should motivate participants to strive to realize their full potential which could in turn be beneficial to the field as whole.

Why to attend?

Antibiotics 2024 is a platform to discuss and learn about the latest advancements in the field of Antibiotics and Antibiotic Resistance as the world’s consideration turned regarding the urgency of new antibiotics as the antimicrobial resistance is growing day by day. Many developed nations and International health organizations are trying to focus of the current situation and making new policies to prevent the adverse effects of Antibiotic resistance.

The 2-day conference gathers Researchers, academia, labs, Drug Manufacturers, government agencies, health professionals, hospitals, young investigators, Pharma and labs and presents their opinions through key notes, and case study presentations. This conference lays a platform for all the researchers working in the field of Antibiotics to know the latest developments and the current situation of the Antibiotic resistance problem.

Sessions & Tracks

Track: 1 Antibiotics

Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.

Introduction to antibiotic uses and challenges
Basic principles of prescribing antibiotics
Mechanisms of bacteriostatic or bactericidal action
Antibiotic Use Linked to Type 1 Diabetes Diagnosis

Track: 2 The Emergence of Antimicrobial Resistance

Antibiotic resistance invoke especially to the resistance to antibiotics that occurs in common bacteria that cause infection. The easy approach and capability of Antibiotics led to overuse in live-stock raising promotes bacteria to flourish resistance. This led to comprehensive problems with antibiotic resistance. World Health Organization (WHO) classified antimicrobial resistance as a serious hazard and no longer a indicator for the future. Antibiotic resistance is now among every part of the world and its stirring everyone irrespective to the age. When infections become resistant to first-line drugs, more costly therapies must be used. A longer duration of illness and treatment, often in hospitals, increases health care costs as well as the financial burden on families and societies. To help prevent the development of current and future bacterial resistance, it is essential to prescribe antibiotics according to the principles of antimicrobial stewardship, such as specify antibiotics only when they are needed.

Antimicrobial Stewardship
Bacterial antibiotic resistance
Alternate strategy to overcome the problem of antimicrobial resistance worldwide
Mechanism of antimicrobial resistance
Proteomics of antimicrobial resistance
Antimicrobial resistance
A public approach to antimicrobial resistance
Novel antibacterial drug discovery
Preventing drug resistance

Related Societies: Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology, British Society for Antimicrobial Chemotherapy

Track: 3 Antibiotic Resistance: Opportunities and Challenges

Certain bacterial infections now oppose all antibiotics. The resistance problem may be reversible, but only if society begins to acknowledge how the drugs affect "good" bacteria as well as "bad". Historically, most antibacterials were used in hospitals, where they were integrated into surgical clothes and soaps to limit the spread of infection. More recently, however, those substances (including triclosan, triclocarbon and such quaternary ammonium compounds as benzalkonium chloride) have been mixed into lotions, dish-washing detergents and soaps meant for general consumers. They have also been impregnated into such items as cutting boards, toys, high chairs and mattress pads.

Antibiotics and alternatives
Grand challenges – antimicrobial resistance
Systemic intervention – values, conflict and blue room resolution
Intervention against antimicrobial resistance – approaches and implementation

Track: 4 Different Types of Antibiotics

Antibiotics are also noted as antibacterials, are types of medications that destroy or slow down the growth of bacteria. Alexander Fleming discovered first penicillin, the first chemical compound with antibiotic properties. Some of the common antibiotics are Aminoglycosides, Cephalosporins, Carbapenems, Macrolides, Penicillin, Quinolones, Sulfonamides and, Tetracyclines etc. General fundamentals of antibiotic prescribing are use: First-line antibiotics first, Reserve broad spectrum antibiotics for marked circumstances only, prescribe antibiotics for bacterial infections if Symptoms are significant or severe.

Hypocholesterolemic agents
Lipopeptide
Macrolides
Monobactams
Nitrofurans
Oxazolidinones
Polypeptides

Track: 5 Applications of Antibiotics

Choice of relevant antibiotics is presently based on individual patient need. Preservation of bacterial sensitivity needs perceptive of how antibiotics select resistance. ‘Ten commandments’ which might be considered carefully when a preference has to be made for antibiotic prescribing. The compelling importance of the fact that all healthcare personnel should take ownership of the need to specify accordingly and to practice effective infection control. A realization that antibiotics may not be competent for the tasks required of them and eventually, with widespread resistance, may be incapable of the task they do today.

Hypocholesterolemic agents
Lipopeptide
Macrolides
Monobactams
Immunosuppressive agents

Track: 6 Methicillin-Resistant Staphylococcus Aureus (MRSA)

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a form of contagious bacterial infection. People sometimes call it a superbug because it is resistant to numerous antibiotics. In healthy people, MRSA does not usually cause a severe infection, but older people, individuals with health conditions, and those with a weakened immune system may be at risk. MRSA is a common and potentially serious infection that has developed resistance to several types of antibiotics. These include methicillin and related antibiotics, such as Penicillin, Vancomycin, and Oxacillin. This resistance makes MRSA difficult to treat. Most MRSA infections occur in people who've been in hospitals or other health care settings, such as nursing homes and dialysis centers. When it occurs in these settings, it's known as health care-associated MRSA (HA-MRSA). HA-MRSA infections typically are associated with invasive procedures or devices, such as surgeries, intravenous tubing or artificial joints. Another type of MRSA infection has occurred in the wider community among healthy people. This form, community-associated MRSA (CA-MRSA), often begins as a painful skin boil. It's spread by skin-to-skin contact.

Track: 7 Antimicrobial Therapy

An antimicrobial therapy kills or inhibits the growth of microorganisms such as bacteria, fungi, or protozoans. Antimicrobial agents are some of the most widely, and often used therapeutic drugs worldwide. It contributes significantly to the quality of life of many people and reduces the morbidity and mortality due to infectious disease. The remarkable success of antimicrobial therapy has been achieved with comparatively little toxicity and expense

Track: 8 Antimicrobial Peptides

Antimicrobial peptides (AMPs), also called Host Defence Peptides (HDPs) are part of the innate immune response found among all classes of life. AMPs have a broad spectrum of targeted organisms ranging from viruses to parasites. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as Immunomodulatory

Track: 9 Antibiotics for Various Diseases and Infections

Antibiotics are amidst the most regularly recommended medications in modern medicine. Antibiotics are useless against viral infections. When you take antibiotics, follow the guidelines carefully. It is important to finish your medicine even if you feel improved. If you stop treatment too soon, some bacteria may survive and re-infect you. Do not save antibiotics for later or use someone else's prescription

Novel antibacterial drug discovery
Skin and soft tissue infections
Urinary tract infections
Acute diarrhea, gastroenteritis, and food poisoning (Campylobacteriosis)
Common gynecologic Infections
Fever and apparent acute central nervous system Infection

Track: 10 Antibiotic Prophylaxis

Antimicrobial prophylaxis is generally used by clinicians for the prevention of numerous infectious diseases. Optimal antimicrobial agents for prophylaxis should be nontoxic, inexpensive, bactericidal and active against the typical pathogens that can motive surgical site infection postoperatively. To maximize its effectiveness, intravenous perioperative prophylaxis should be carried out within 30 to 60 minutes before the surgical incision. Antimicrobial prophylaxis should be of short time to downturn toxicity and antimicrobial resistance and to reduce cost.

Prevention of microbial infection
Antibiotic selection
Advantages of long-acting antibiotics
Antibiotics in aquaculture

Track: 11 Immunology:

The study of the immune system is known as immunology, and it is important to the biological and medical sciences. We are protected from infection by the immune system thanks to several levels of defence. Diseases including cancer, allergies, and autoimmunity will develop if the system is not operating properly. The immune response is a biological mechanism that recognises and gets rid of antigen substances in addition to being the body's reaction to antigen stimulation. The majority of immune system components are cellular in nature and unrelated to any one organ, yet they are implanted or circulating in different tissues all over the body. Immunology has applications in countless medical disciplines, especially in the fields of Organ Transplantation, Virology, Oncology, Rheumatology, Bacteriology, Parasitology and Dermatology.

Track: 12 Infectious Diseases:

Infectious diseases are illnesses caused by pathogenic microorganisms such as viruses, bacteria, parasites, or fungi that can be transmitted from one person to another either directly or indirectly (vector-borne). The invasion of disease-causing pathogens into an organism's body tissues, their growth, and the host tissues' response to the infectious agents and the toxins they produce are all considered to be infections. A condition brought on by an infection is referred to as an infectious disease, often known as a transmissible or communicable sickness. There are many different pathogens that can cause infections, but bacteria and viruses are the most prevalent ones. Hosts' immune systems can aid in their ability to combat disease. The medical specialty that deals with infections is referred to as infectious disease.

Influenza
Cryptosporidiosis
Vector-Borne Diseases
Legionnaires’ Disease
Human Metapneumovirus
Antibiotic-Resistant Diseases
Valley Fever
Immunity and Infectious Diseases

Track: 14 Antibiotics: In Pregnancy and Lactation

Antibiotics are frequently recommended during pregnancy. The specific medication must be chosen carefully, however. Some antibiotics are prescribed to take during pregnancy, while others are not. Safety depends on various factors, including the type of antibiotic, when in pregnancy you take the antibiotic, how much you take and for how long. Antibiotics normally advised safe during pregnancy: Ampicillin, Amoxicillin, Clindamycin, Erythromycin, Penicillin, Nitrofurantoin. Despite there's no direct clue that these antibiotics cause birth defects, additional research is needed. In the interim, use of these medications is still assured in some cases.

Safe use of anti‐infective agents
Current investigations in broad spectrum antibiotics
Antibiotics and neurological damage

Track: 15 Antibiotics in Different Industries

Antibiotics must be used accordingly in humans and animals because both uses share to the emergence, persistence, and escalation of resistant bacteria. Resistant bacteria in food-producing animals are of particular concern. Food animals play as a source of resistant pathogens and resistance mechanisms that can directly or indirectly result in antibiotic resistant infections in humans. Resistant bacteria may be transmitted to humans through the foods we eat. Some bacteria have turned resistant to more than one sort of antibiotic, which makes it more difficult to treat the infections they cause. Sustaining the efficiency of antibiotic drugs is vital to insulating human and animal health.

Antibiotics in food Industry
Antibiotics in agriculture
Antibiotics in veterinary

Track: 16 Antibiotics for Emerging and Re-emerging Diseases

New diseases are originating globally and old diseases are re-emerging as Infectious agents evolve or spread, and as changes occur in conservation, socio-economic conditions, and population patterns. Likewise, many diseases thought to be decently controlled appear to be making a revival. In developed countries, public health measures such as sewage treatment, vaccination programs, sanitation and access to good medical care-including a wide range of antibiotics-have virtually disposed “traditional” diseases such as tuberculosis, diphtheria and whooping cough

Resistance and re-emerging theories
Medication procedures
Molecular mechanism of resistance
New drugs for emerging diseases

Track: 17 Antibiotics and Mechanism of Action

Antibacterial action customarily falls within one of four mechanisms, three of which involve the inhibition or regulation of enzymes tangled in cell wall biosynthesis, nucleic acid metabolism and repair, or protein synthesis, respectively. The fourth mechanism associates the interruption of membrane structure. Many of these cellular functions targeted by antibiotics are most effective in multiplying cells. Since there is often overlap in these functions between eukaryotic mammalian cells and prokaryotic bacterial cells, it is not surprising that some antibiotics have also been found to be useful as anticancer agents.

Broad spectrum
Narrow spectrum
Nuclear material
Protein
Pharmacokinetics of Antibiotics
Pharmacodynamics of Antibiotics

Track: 18 Micro Organisms in Recent Drug Discovery

Environmental microbes are a leading source of drug discovery, and several microbial products ( anti-tumour products, antibiotics, immunosuppressants and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary way of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenario to swamped such constraints that might further expand the promise of drugs from environmental microbes

Novel species discovery
Micos from different areas (patients, geographical locations)
Genetically modified organisms

Track: 19 Drug Discovery and Novel Delivery Technologies

In the prior most drugs have been invented either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new access has been to recognize how disease and infection are controlled at the molecular and physiological level and to mark specific entities based on this knowledge. The process of drug discovery involves the identification of candidates, characterization, screening, synthesis, and assays for therapeutic efficacy. Evolution of an existing drug molecule from a ordinary form to a novel delivery system can significantly improve its performance in terms of patient compliance, efficacy and safety. These days, drug delivery companies are engaged in the development of numerous platform technologies to get ambitious advantage, extend patent life, and increase market share of their products. Formerly a compound has displayed its value in these tests; it will begin the process of drug development prior to clinical trials.

Policies to stimulate drug development and discovery
Role of computational biology
Ligand binding studies
Transport (simulation studies)
Molecule mediating transport

Track: 21 Antibiotics: Market Analysis and Business Opportunities

The global antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%. From, 2005 this market is seen to grow at an annual rate of 6.6% until 2011. There are many companies producing antibiotics these days and there are many other antibiotics present in the market such as aminoglycoside antibiotics and it cap around 79% of the global demand. Moreover, the other antibiotics such as penicillin have 8%, streptomycin 1%, chloramnphenicol 1 %, tetracyclines 4%, erythromycin has 7%, market.

Global antibiotics market
Antibiotics market Europe
Antibiotics market USA
Antibiotics market UK

Track: 22 Clinical Trials of Antibiotics

Prescribing doctors are, progressively, using clinical trial data as a major source of information for evidence-based medicine for the remedy of infectious diseases, as in other clinical disciplines. However, it may be difficult to excerpt from these data the material that is needed for the management of the individual patient. At the same time, clinical trial testimony have been used, probably satisfactorily, in the process of drug registration, and the pharmaceutical industry has spent progressively large amount of money to satisfy the needs of this process. In the face of all these problems, switch in the way antibiotic clinical trials are designed and performed are clearly necessary, although this must not disturb the balance so far as to restore them less useful for those who currently derive greatest benefit from them.

Evaluations of efficacy
Evaluations of safety
Clinical biochemistry & clinical microbiology

Track: 23 Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs

The pharmacodynamics of an antimicrobial drug relates its pharmacokinetics to the time course of the antimicrobial effects at the site of the infection. Knowledge of the drug's antimicrobial pharmacodynamics effects provides a more rational basis for determination of optimal dosing regimens in terms of the dose and the dosing interval than do the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) determined in vitro. This session mainly focus on pharmacokinetics, antimicrobial pharmacodynamics, the effect of pharmacodynamics on the emergence of resistant bacterial subpopulations, and the development of pharmacodynamics breakpoints for use in the design of trials of these drugs and in the treatment of infected patients

Track: 24 Prevention and Control of Antibiotic Resistance

Antimicrobial resistance is a complex problem with many diverse contributing factors. It is major cause of health concerns adding cost to oneself and to the community, directly or indirectly. Prevention is still the best tool to reduce the infection spread and thereby AMR. Along with rational use of existing antimicrobial drugs, development of new effective compounds and new diagnostic technology is the need. Joint efforts from patients, prescribers and individuals to international regulators and policy makers are needed to fight against the globally spreading antimicrobial resistance.

Track: 25 Current Research in Antibiotic Resistance

Antibiotic overuse and misuse has led to a growing number of bacteria in humans, animals and the environment that are resistant to life-saving antimicrobial therapies. Urgent action is needed to halt the development of resistance, and to accelerate new treatments for bacterial infection. Research includes epidemiology of both Gram-negative and Gram-positive infections, genetic mechanisms of resistance, evolution and transmission in the hospital setting, as well as the community, and antimicrobial stewardship

Track: 26 The Next Generation Approach of Antibiotics

As research into antibiotic resistance expands, it is important to adopt an explicitly proactive approach to antibiotic resistance identification and surveillance, as well as antibiotic therapy development. This proactive approach involves using a combination of functional metagenomics, next-generation sequencing and cutting-edge computational methods to monitor the evolution and dissemination of resistance before a given resistance determinant emerges in a pathogen or in the clinical setting, as well as proactively developing next-generation therapies that target these resistance determinants. Recent advances in the field highlight the promise that the next generation of resistome studies hold for characterizing and countering emerging resistance threats

Track: 27 Developing Alternatives to Antibiotics

Alternatives to antibiotics are broadly defined as any substance that can be substituted for therapeutic drugs that are increasingly becoming ineffective against pathogenic bacteria due to antimicrobial resistance. Although antibiotics remain an essential tool for treating animal diseases on the farm, the availability of effective medical interventions to prevent and control animal diseases is one of the most significant challenges facing veterinary medicine in the 21st century. Phytochemicals as antibiotic alternatives to promote growth and enhance host health. Innovative drugs, chemicals, and enzymes within the animal production chain. Vaccines as alternatives to antibiotics for food producing animals. Also recent research provides numerous possibilities for the application nanomaterials in broad-spectrum eradication of pathogenic bacteria with many applications such as skin pathogen infection, implant sterilization, and wastewater treatment.

Track: 28 Pharmacology & Toxicology

Pharmacology is a branch in science concerned with the effects of the drugs on living organisms (pharmacodynamics) and the effects of living organisms with the drugs (pharmacokinetics). This subject embodies drug composition and properties, interactions, toxicology, therapy, and medicinal uses such as application and antipathogenic capabilities. Pharmacology is subdivided into two categories as mentioned above, pharmacodynamics and pharmacokinetics. Pharmacodynamics deals with chemical interactions with body/cell receptors. Pharmacokinetics, on the other hand, deals with the four stages of chemicals passing through the body: absorption, distribution, metabolism and excretion. Toxicology is the scientific study of adverse effects that occur in living organisms due to chemicals. It involves observing and reporting symptoms, mechanisms, detection and treatments of toxic substances, in particular relation to the poisoning of humans. It includes environmental agents and chemical compounds found in nature, as well as pharmaceutical compounds that are synthesized for medical use by humans. These substances may produce toxic effects in living organisms including disturbance in growth patterns, discomfort, disease and death.

Advances in pharmacological testing
Medicine development and safety testing
Dose response relation in psychiatric medications
Nutritional deficiency and disorders

Track: 30 Pre-clinical and Clinical Trails

In drug development, preclinical development, also named preclinical studies and nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative testing and drug safety data are collected. The main goals of pre-clinical studies are to determine the safe dose for first-in-man study and assess a product's safety profile. Products may include new medical devices, drugs, gene therapy solutions and diagnostic tools. On average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug

Track: 31 Drug Safety Testing

Drug safety testing is happening in a growing number of countries including Austria, Canada, Colombia, Mexico, the Netherlands, Switzerland, United States and the UK. This briefing discusses testing using sophisticated analytical equipment, not DIY kits that cannot identify many contaminants, or strength. Drug safety testing is happening in a growing number of countries including Austria, Canada, Colombia, Mexico, the Netherlands, Switzerland, United States and the UK. This briefing discusses testing using sophisticated analytical equipment, not DIY kits that cannot identify many contaminants, or strength.

Drug formulation
Drug mechanism
Drug dosage
Drug dosage

Track: 32 Clinical Pharmacy and Pharmacotherapeutics

Clinical pharmacy is the discipline of Pharmacy where pharmacists are meant to provide patient care which helps in optimizing the use of drugs and improves health, wellness, and prevents diseases. This session is dealt with topics like basic components of clinical pharmacy practice Prescribing drugs, Reviewing drug use, Administering drugs, Counseling, Documenting professional services, Consulting, Preventing Medication Errors etc.,

Drug development and interactions
Receptor theory for drug effects
Pharmacokinetic and pharmacodynamic parameters

Track: 33 Drug Screening and Discovery

All pharmaceutical researchers know the feeling. Somewhere out there must be that elusive molecule — one that will inhibit this enzyme or activate that receptor in the way they want, and without causing unwanted side-effects. But finding it is another matter. For small-molecule drugs — the mainstay of the pharmaceutical industry — time-consuming and expensive screening is needed to pick out promising candidates from the vast number of natural and synthetic compounds available. Testing large numbers of compounds to see if they produce an appropriate biochemical or cellular effect is usually one of the first steps in the drug-discovery pathway, and ways of making this screening faster, more effective and less expensive are in continual development.

Drug dosage
Innovative Drug Delivery Technologies
Implantable Drug Delivery System
Pediatric Drug Delivery systems
Routes of Drug Administration

Track: 34 Clinical Research Statistics

Statistical analysis is one of the foundations of evidence-based clinical practice, a key in conducting new clinical research and in evaluating and applying prior research. In this paper, we review the choice of statistical procedures, analyses of the associations among variables and techniques used when the clinical processes being examined are still in process. We discuss methods for building predictive models in clinical situations, and ways to assess the stability of these models and other quantitative conclusions. Techniques for comparing independent events are distinguished from those used with events in a causal chain or otherwise linked. Attention then turns to study design, to the determination of the sample size needed to make a given comparison, and to statistically negative studies.

Track: 35 Adverse Drug Reactions

Adverse drug reactions can be considered a form of toxicity; however, toxicity is most commonly applied to effects of overingestion (accidental or intentional) or to elevated blood levels or enhanced drug effects that occur during appropriate use (eg, when drug metabolism is temporarily inhibited by a disorder or another drug). For information on toxicity of specific drugs see the table Symptoms and Treatment of Specific Poisons. Side effect is an imprecise term often used to refer to a drug’s unintended effects that occur within the therapeutic range.

Because all drugs have the potential for adverse drug reactions, risk-benefit analysis (analyzing the likelihood of benefit vs risk of ADRs) is necessary whenever a drug is prescribed.

In the US, 3 to 7% of all hospitalizations are due to adverse drug reactions. ADRs occur during 10 to 20% of hospitalizations; about 10 to 20% of these ADRs are severe. These statistics do not include the number of ADRs that occur in ambulatory and nursing home patients. Although the exact number of ADRs is not certain, ADRs represent a significant public health problem that is, for the most part, preventable.

Market Analysis

Antibiotics 2024 Market Analysis

The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 58,142.92 million in 2024, witnessing a CAGR of 4.7%.The Antibacterial Drugs market is expected to cross US$ 48 Billion by 2025 growing at a CAGR of 1% during the given forecast period. Rising pervasiveness of irresistible illnesses particularly in creating locales, for example, Asia Pacific and MEA is foreseen to contribute towards showcase development.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players include Allergen plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Merck & Co., Inc. Novartis AG, Pfizer, Inc., and Sanofi.

The antibiotics market generated sales of US$42 billion in 2009 globally, representing 46% of sales of anti-infective agents (which also include antiviral drugs and vaccines) and 5% of the global pharmaceutical market. However, the antibiotics market is maturing; it showed an average annual growth of 4% over the past 5 years, compared with a growth of 16.7% and of 16.4% for antiviral drugs and vaccines, respectively.

Over 15.0% of the passing’s, in kids underneath the age of five, are assessed to be because of pneumonia and as indicated by the insights given by the WHO around 9.2 million passing’s were recorded in 2015. Like tuberculosis, the most elevated commonness of the sickness is recognized to be in the South Asian and Sub-Saharan locales. At present, the required anti-infection treatment is accessible just to 33% of the tainted populace, subsequently expanding the illness trouble.

The major driving factors of Antibacterial Drugs Market are as follows:

There is a very high prevalence of infectious diseases.
The research and development activities have increased.
Product differentiation through various methods.
Increased government support.

The restraining factors of Antibacterial drugs Market is as follows:

Rise in drug resistant species.
Launch of the generic drugs.
Patent expiry

Importance and Scope

Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.

Where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse. Similarly, in countries without standard treatment guidelines, antibiotics are often over-prescribed by health workers and veterinarians and over-used by the public. Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.

Target Audience

Healthcare Students, Scientists, and professors
Doctors
Microbiologist
Infectious diseases specialists
Antimicrobial scientists
Pharmacists
Public health experts
Laboratorist
Bacteriology Researchers
Faculty of bacteriology and infectious diseases
Medical Colleges
Healthcare Associations and Societies
Business Entrepreneurs

Related Companies

Gilead Sciences
Pfizer
Abbott Laboratories
Merck & Co
Eli Lilly
Astellas Pharma
Teva Pharmaceutical Industries
Boehringer Ingelheim
Roche
Mylan
3-D Matrix
Agilent
BeiGene
BioDuro
Fosun Pharma

To Collaborate Scientific Professionals around the World

Conference Date March 14-15, 2024

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Antibiotics 2023 Conference

Supported By

Journal of Drug Metabolism & Toxicology Advances in Pharmacoepidemiology and Drug Safety Drug Designing: Open Access

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Antibiotics and Antibiotic Resistance

March 14-15, 2024 London, UK

Use antibiotic wisely-Prevent antimicrobial resistance

Conference Series Conferences gaining more Readers and Visitors